FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W228280975> ?p ?o ?g. }

• W228280975 endingPage "S2" @default.
• W228280975 startingPage "S1" @default.
• W228280975 abstract "Since the early 1970s, the US incidence of coronary artery disease (CAD) has been decreasing mostly because of a reduction in cigarette smoking and low-density lipoprotein (LDL) cholesterol levels. However, the rate of decrease is slowing because of the aging of the US population and an increasing prevalence of metabolic syndrome driven by the epidemic of obesity.1Menotti A. Lanti M. Kromhout D. Blackburn H. Nissinen A. Dontas A. Kafatos A. Nedeljkovic S. Adachi H. Forty-year coronary mortality trends and changes in major risk factors in the first 10 years of follow-up in the seven countries study.Eur J Epidemiol. 2007; 22: 747-754Crossref PubMed Scopus (48) Google Scholar LDL cholesterol is less predictive of CAD today than in earlier trials, and although the achievement of established LDL cholesterol treatment targets is improving, there remains significant residual risk for CAD events.2Davidson M.H. Reducing residual risk for patients on statin therapy: the potential role of combination therapy.Am J Cardiol. 2005; 96 (discussion 34K–35K): 3K-13KAbstract Full Text Full Text PDF PubMed Scopus (73) Google Scholar Almost 50% of patients >50 years of age have metabolic syndrome and, therefore, multiple CAD risk factors. Ideally, all CAD risk factors should be well controlled, and increasing evidence shows an enhanced benefit with the more aggressively each individual risk factor is modified.3Lakka H.M. Laaksonen D.E. Lakka T.A. Niskanen L.K. Kumpusalo E. Tuomilehto J. Salonen J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.JAMA. 2002; 288: 2709-2716Crossref PubMed Scopus (3966) Google Scholar Therefore, clinicians are confronted with 2 important challenges: appropriate identification of patients with moderate or intermediate risk in whom pharmacologic therapy should be initiated, and after initiating therapy, determination of the degree of global risk management necessary to adequately reduce CAD risk. Dr. Paul Ridker4Ridker P.M. High sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit.Am Heart J. 2004; 148: S19-S26Abstract Full Text Full Text PDF PubMed Scopus (208) Google Scholar has pioneered the use of the inflammatory marker high-sensitivity C-reactive protein (hs-CRP) as a valid biomarker to enhance CAD risk prediction and perhaps, determine the adequacy of risk factor modification. The hs-CRP marker has been shown to be an excellent and consistent predictor of primary CAD events and identifier of patients in statin clinical trials who have events despite adequately controlled LDL cholesterol levels. In addition, therapeutic approaches that lower hs-CRP levels reduce cardiovascular disease (CVD) events, whereas therapies that adversely affect hs-CRP (estrogen and torcetrapib) did not improve outcomes in clinical trials. Therefore, with a few exceptions (ie, rosiglitazone, raloxifene), therapeutic agents that lower hs-CRP also reduce CVD, and patients with lower hs-CRP levels have better outcomes. The discovery of hs-CRP has provided an important link between inflammation and increased CVD risk. This paradigm shift has led to efforts to identify other inflammatory biomarkers that may add to the risk prediction enhancements of hs-CRP. Another interesting and well-studied biomarker is lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is directly involved in the pathogenesis of atherosclerotic plaque progression and may not only be a biomarker for risk prediction, but also may represent a novel therapeutic target to reduce the disease process.5Garza C.A. Montori V.M. McConnell J.P. Somers V.K. Kullo I.J. Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.Mayo Clin Proc. 2007; 82: 159-165Abstract Full Text Full Text PDF PubMed Scopus (180) Google Scholar In this supplement to The American Journal of Cardiology, experts in the field of biomarkers, cardiovascular risk, and stroke have provided important reviews of the data on Lp-PLA2. In the first article, Dr. Howard S. Weintraub illuminates the identification of the vulnerable patient with rupture-prone plaque. Next, Drs. Amir Lerman and Joseph P. McConnell discuss the pathophysiology of Lp-PLA2 and its direct causal role in vascular inflammation and plaque rupture. Then, Dr. Jeffrey L. Anderson reviews published studies on Lp-PLA2 as a risk marker in the primary and secondary prevention of coronary and cardiovascular events. In the fourth article, the relation between Lp-PLA2 measurement and stroke risk is explored by Dr. Philip Gorelick. Then, Dr. Marshall Corson et al provide a comprehensive review of the current literature and summarize the key points of the other authors in their articles in this supplement. Finally, recommendations by an expert panel on how Lp-PLA2 testing might be used in conjunction with guideline-endorsed CVD risk assessment in an effort to create more aggressive risk reduction strategies. The author who contributed to this article has disclosed the following industry relationships. Michael H. Davidson, MD is a member of the Speakers' Bureau for Abbott Laboratories, AstraZeneca Pharmaceuticals, Daiichi-Sankyo, Inc., diaDexus, Inc., Merck & Co., Inc., Merck/Schering-Plough, Oscient Pharmaceuticals, Pfizer, Inc, and Takeda Pharmaceuticals; is a consultant for Abbott Laboratories, AstraZeneca Pharmaceuticals, Daiichi-Sankyo, Inc., diaDexus, Inc., Merck & Co., Inc., Merck/Schering-Plough, Pfizer, Inc, Roche Pharmaceuticals, sanofi aventis, and Takeda Pharmaceuticals; has received grant/research support from Abbott Laboratories, AstraZeneca Pharmaceuticals, Daiichi-Sankyo, Inc., Merck & Co., Inc., Merck/Schering-Plough, Pfizer, Inc., Roche Pharmaceuticals, and Takeda Pharmaceuticals; is on the advisory board for Abbott Laboratories, Access Health, Atherogenics, AstraZeneca Pharmaceuticals, Daiichi-Sankyo, Inc., Merck & Co., Inc., Merck/Schering-Plough, Oscient Pharmaceuticals, Pfizer, Inc., Roche Pharmaceuticals, and Takeda Pharmaceuticals; is on the Board of Directors for Angiogen and Sonogene; and is Chief Medical Officer of Professional Evaluation, Inc." @default.
• W228280975 created "2016-06-24" @default.
• W228280975 creator A5055380940 @default.
• W228280975 date "2008-06-01" @default.
• W228280975 modified "2023-09-27" @default.
• W228280975 title "Introduction" @default.
• W228280975 cites W2048186816 @default.
• W228280975 cites W2060449981 @default.
• W228280975 cites W2070336409 @default.
• W228280975 cites W2084102521 @default.
• W228280975 doi "https://doi.org/10.1016/j.amjcard.2008.04.012" @default.
• W228280975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18549866" @default.
• W228280975 hasPublicationYear "2008" @default.
• W228280975 type Work @default.
• W228280975 sameAs 228280975 @default.
• W228280975 citedByCount "0" @default.
• W228280975 crossrefType "journal-article" @default.
• W228280975 hasAuthorship W228280975A5055380940 @default.
• W228280975 hasBestOaLocation W2282809751 @default.
• W228280975 hasConcept C120665830 @default.
• W228280975 hasConcept C121332964 @default.
• W228280975 hasConcept C126322002 @default.
• W228280975 hasConcept C152163801 @default.
• W228280975 hasConcept C164705383 @default.
• W228280975 hasConcept C17744445 @default.
• W228280975 hasConcept C199539241 @default.
• W228280975 hasConcept C2776839432 @default.
• W228280975 hasConcept C2778163477 @default.
• W228280975 hasConcept C2778213512 @default.
• W228280975 hasConcept C2779134260 @default.
• W228280975 hasConcept C2779473830 @default.
• W228280975 hasConcept C2780578515 @default.
• W228280975 hasConcept C2908647359 @default.
• W228280975 hasConcept C50440223 @default.
• W228280975 hasConcept C511355011 @default.
• W228280975 hasConcept C61511704 @default.
• W228280975 hasConcept C71924100 @default.
• W228280975 hasConcept C83867959 @default.
• W228280975 hasConcept C99454951 @default.
• W228280975 hasConceptScore W228280975C120665830 @default.
• W228280975 hasConceptScore W228280975C121332964 @default.
• W228280975 hasConceptScore W228280975C126322002 @default.
• W228280975 hasConceptScore W228280975C152163801 @default.
• W228280975 hasConceptScore W228280975C164705383 @default.
• W228280975 hasConceptScore W228280975C17744445 @default.
• W228280975 hasConceptScore W228280975C199539241 @default.
• W228280975 hasConceptScore W228280975C2776839432 @default.
• W228280975 hasConceptScore W228280975C2778163477 @default.
• W228280975 hasConceptScore W228280975C2778213512 @default.
• W228280975 hasConceptScore W228280975C2779134260 @default.
• W228280975 hasConceptScore W228280975C2779473830 @default.
• W228280975 hasConceptScore W228280975C2780578515 @default.
• W228280975 hasConceptScore W228280975C2908647359 @default.
• W228280975 hasConceptScore W228280975C50440223 @default.
• W228280975 hasConceptScore W228280975C511355011 @default.
• W228280975 hasConceptScore W228280975C61511704 @default.
• W228280975 hasConceptScore W228280975C71924100 @default.
• W228280975 hasConceptScore W228280975C83867959 @default.
• W228280975 hasConceptScore W228280975C99454951 @default.
• W228280975 hasIssue "12" @default.
• W228280975 hasLocation W2282809751 @default.
• W228280975 hasLocation W2282809752 @default.
• W228280975 hasOpenAccess W228280975 @default.
• W228280975 hasPrimaryLocation W2282809751 @default.
• W228280975 hasRelatedWork W2002530672 @default.
• W228280975 hasRelatedWork W2015515593 @default.
• W228280975 hasRelatedWork W2033114569 @default.
• W228280975 hasRelatedWork W2070336409 @default.
• W228280975 hasRelatedWork W2095512786 @default.
• W228280975 hasRelatedWork W2095676139 @default.
• W228280975 hasRelatedWork W2109158498 @default.
• W228280975 hasRelatedWork W2141121157 @default.
• W228280975 hasRelatedWork W2363823760 @default.
• W228280975 hasRelatedWork W3036847879 @default.
• W228280975 hasVolume "101" @default.
• W228280975 isParatext "false" @default.
• W228280975 isRetracted "false" @default.
• W228280975 magId "228280975" @default.
• W228280975 workType "article" @default.